Nothing Special   »   [go: up one dir, main page]

CY1123043T1 - Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων - Google Patents

Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων

Info

Publication number
CY1123043T1
CY1123043T1 CY20201100321T CY201100321T CY1123043T1 CY 1123043 T1 CY1123043 T1 CY 1123043T1 CY 20201100321 T CY20201100321 T CY 20201100321T CY 201100321 T CY201100321 T CY 201100321T CY 1123043 T1 CY1123043 T1 CY 1123043T1
Authority
CY
Cyprus
Prior art keywords
chemotherapy
treatment
combination therapies
resistant cancer
combination
Prior art date
Application number
CY20201100321T
Other languages
English (en)
Inventor
Daniel P. Gold
Guillermo Garcia-Manero
Original Assignee
Mei Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma, Inc. filed Critical Mei Pharma, Inc.
Publication of CY1123043T1 publication Critical patent/CY1123043T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Παρέχονται εδώ μέθοδοι θεραπείας μιας νόσου ή διαταραχής που σχετίζεται με απορρύθμιση δεακετυλάσης ιστόνης, και πλέον συγκεκριμένα ευαισθητοποίηση και θεραπεία ανθεκτικών στη χημειοθεραπεία καρκίνων, που περιλαμβάνει χορήγηση μιας θεραπευτικά αποτελεσματικής ποσότητας ενός συνδυασμού που περιλαμβάνει μία ένωση βενζιμιδαζολίου και έναν παράγοντα υπομεθυλίωσης DΝΑ, και κιτ τα οποία περιέχουν τον εν λόγω συνδυασμό. Ο προτιμώμενος παράγοντας υπομεθυλίωσης DΝΑ που χρησιμοποιείται στη μέθοδο είναι 5-αζακυτιδίνη (αζακιτιδίνη).
CY20201100321T 2012-10-30 2020-04-06 Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων CY1123043T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261720346P 2012-10-30 2012-10-30
PCT/US2013/067607 WO2014070948A1 (en) 2012-10-30 2013-10-30 Combination therapies

Publications (1)

Publication Number Publication Date
CY1123043T1 true CY1123043T1 (el) 2021-10-29

Family

ID=50628036

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100321T CY1123043T1 (el) 2012-10-30 2020-04-06 Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων

Country Status (15)

Country Link
US (2) US20150258068A1 (el)
EP (2) EP3662911A1 (el)
JP (1) JP6343285B2 (el)
CA (1) CA2927565C (el)
CY (1) CY1123043T1 (el)
DK (1) DK2914254T3 (el)
ES (1) ES2774296T3 (el)
HR (1) HRP20200521T1 (el)
HU (1) HUE048584T2 (el)
LT (1) LT2914254T (el)
PL (1) PL2914254T3 (el)
PT (1) PT2914254T (el)
RS (1) RS60122B1 (el)
SI (1) SI2914254T1 (el)
WO (1) WO2014070948A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142589A (en) 2003-09-22 2010-12-15 S Bio Pte Ltd Benzimidazole derivatives : preparation and pharmaceutical applications
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
AR108257A1 (es) * 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2019157087A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
JP2022511746A (ja) * 2018-11-30 2022-02-01 エムイーアイ ファーマ，インク． 高リスクの、および非常に高リスクのｍｄｓのための併用療法
JP7115401B2 (ja) 2019-04-10 2022-08-09 株式会社デンソー モータ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20100098691A1 (en) * 2001-01-24 2010-04-22 S'bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
WO2003066889A2 (en) 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
MY144970A (en) * 2005-09-08 2011-11-30 S Bio Pte Ltd Heterocyclic compounds
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN104557914A (zh) * 2008-09-26 2015-04-29 新加坡科技研究局 3-脱氮瓶菌素衍生物

Also Published As

Publication number Publication date
HUE048584T2 (hu) 2020-08-28
HRP20200521T1 (hr) 2020-08-07
EP2914254A1 (en) 2015-09-09
PL2914254T3 (pl) 2020-09-07
ES2774296T3 (es) 2020-07-20
CA2927565C (en) 2021-05-18
EP2914254B1 (en) 2020-01-08
CA2927565A1 (en) 2014-05-08
WO2014070948A1 (en) 2014-05-08
PT2914254T (pt) 2020-04-02
EP2914254A4 (en) 2016-06-29
US20150258068A1 (en) 2015-09-17
JP2016501838A (ja) 2016-01-21
SI2914254T1 (sl) 2020-07-31
JP6343285B2 (ja) 2018-06-13
DK2914254T3 (en) 2020-03-30
EP3662911A1 (en) 2020-06-10
LT2914254T (lt) 2020-04-27
US20210100775A1 (en) 2021-04-08
RS60122B1 (sr) 2020-05-29

Similar Documents

Publication Publication Date Title
CY1123043T1 (el) Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
CY1118695T1 (el) Αναστολεις απομεθυλασων ιστονων
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
WO2016025635A3 (en) Combination therapy for treating cancer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
EP3148336A4 (en) Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.